Abstract
The majority of melanoma cells do not express argininosuccinate synthetase (ASS), and hence cannot synthesize arginine from citrulline. Their growth and proliferation depend on exogenous supply of arginine. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death while normal cells which express ASS can survive. This notion has been translated into clinical trial. Pegylated ADI (ADI-PEG20) has shown antitumor activity in melanoma. However, the sensitivity to ADI is different among ASS(-) melanoma cells. We have investigated and reviewed the signaling pathways which are affected by arginine deprivation and their consequences which lead to cell death. We have found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF. These changes most likely lead to autophagy, a possible mechanism to survive by recycling intracellular arginine. However apoptosis does occur which can be both caspase-dependent or independent. In order to increase the therapeutic efficacy of this form of treatment, one should consider adding other agent(s) which can drive the cells toward apoptosis or inhibit the autophagic process.
Keywords: Arginine deiminase, argininosuccinate synthetase, melanoma
Current Molecular Medicine
Title: Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Volume: 10 Issue: 4
Author(s): N. Savaraj, M. You, C. Wu, M. Wangpaichitr, M.T. Kuo and L.G. Feun
Affiliation:
Keywords: Arginine deiminase, argininosuccinate synthetase, melanoma
Abstract: The majority of melanoma cells do not express argininosuccinate synthetase (ASS), and hence cannot synthesize arginine from citrulline. Their growth and proliferation depend on exogenous supply of arginine. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death while normal cells which express ASS can survive. This notion has been translated into clinical trial. Pegylated ADI (ADI-PEG20) has shown antitumor activity in melanoma. However, the sensitivity to ADI is different among ASS(-) melanoma cells. We have investigated and reviewed the signaling pathways which are affected by arginine deprivation and their consequences which lead to cell death. We have found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF. These changes most likely lead to autophagy, a possible mechanism to survive by recycling intracellular arginine. However apoptosis does occur which can be both caspase-dependent or independent. In order to increase the therapeutic efficacy of this form of treatment, one should consider adding other agent(s) which can drive the cells toward apoptosis or inhibit the autophagic process.
Export Options
About this article
Cite this article as:
Savaraj N., You M., Wu C., Wangpaichitr M., Kuo M.T. and Feun L.G., Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791316995
DOI https://dx.doi.org/10.2174/156652410791316995 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Structural and Computational Biology of the Molecular Chaperone Hsp90: From Understanding Molecular Mechanisms to Computer-Based Inhibitor Design
Current Topics in Medicinal Chemistry A Review on Chemical Profile of Coumarins and their Therapeutic Role in the Treatment of Cancer
Current Drug Delivery Emerging Immunotargets and Immunotherapies in Prostate Cancer
Current Drug Targets Photothermal Therapy: A New Approach to Eradicate Cancer
Current Nanoscience Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Review of the Biological Activity of Maslinic Acid
Current Drug Targets Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry New Developments in Oral Vaccines and Mucosal Adjuvants
Recent Patents on Inflammation & Allergy Drug Discovery Pyrazole Derivatives as Antitumor, Anti-Inflammatory and Antibacterial Agents
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets